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Operative Hemostasis in Trauma 
and Acute Care Surgery: The Role 
of Biosurgical Agents
Kyle Dammann, Amanda Gifford, Kathryn Kelley  
and Stanislaw P. Stawicki
Abstract
Trauma and acute care surgery (TACS) constitutes the foundation of emergency 
surgical services in the United States. Blunt and penetrating traumatic injuries 
are a leading cause of death worldwide. Non-trauma general surgical emergen-
cies are also a major source of morbidity and mortality. Operative interventions 
performed within the scope of TACS often revolve around the core principles of 
contamination control, hemostasis, surgical repair, and subsequent functional 
restoration. Hemorrhage control is an integral part of emergent operative interven-
tions, and while most instances of surgical bleeding require direct suture ligation 
or some other form of direct tissue intervention, some circumstances call for the 
use of adjunctive means of hemostasis. This is especially applicable to situations 
and settings where direct applications of surgical energy, suture ligation, or direct 
compression are not possible. Difficult-to-control bleeding can be highly lethal and 
operative control can be very challenging when confounded by the lethal triad of 
acidosis, coagulopathy and hypothermia. Topical biosurgical materials (BSM) are of 
great value in such scenarios, and their use across a variety of settings, from pre-
hospital trauma application to emergency general surgery operations, represents 
an important adjunct to improve patient outcomes. Here we present the different 
BSMs, discuss their various uses, and provide insight on future applications and 
developments in this important area.
Keywords: acute care surgery, biosurgical hemostatic agent, injury, operative 
interventions, patient outcomes, trauma
1. Introduction
Achieving and maintaining hemostasis is essential across all subspecialties of 
surgery [1–6]. Direct application of pressure, suture ligation, and electrocautery 
may sufficiently control bleeding during straightforward procedures, however, 
such methods are often ineffective in hemodynamically unstable, coagulopathic or 
septic patients [6–8]. Biosurgical hemostats are increasingly important in facilitat-
ing hemostasis when standard measures prove inadequate, or in situations such as 
prehospital trauma [7, 9]. Biosurgical materials (BSM) are available in cotton-like, 
powder, patch, liquid, and glue format, and are classified based on their properties 
and interactions within the coagulation cascade [5, 10, 11]. The goal of this chapter 
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is to review the many intricacies and molecular physiology of hemostasis, and to 
discuss the current role for biosurgicals within the overall operative strategy, focus-
ing on applications of BSMs in acute care surgery and trauma.
2. Methods
The authors performed an exhaustive medical literature search utilizing PubMed 
and Google Scholar™ platforms. The following terms were utilized, alone or 
various combinations: “acute care surgery,” “biosurgical hemostat,” “biosurgical 
material,” “bleeding,” “coagulopathy,” “emergency surgery,” “hemorrhage,” “hemo-
stasis,” “injury,” “management,” “non-surgical bleeding,” “surgery,” “transfusion,” 
“trauma.” Additional references identified during the primary literature search 
were subsequently reviewed and added. From more than 27,781,100 citations, we 
narrowed down the candidate study list to approximately 1400. The final reference 
list included the 90 results most relevant to the current chapter.
3. Coagulation cascade
The multiprotein coagulation cascade consists of two separate pathways, the 
contact mediated (intrinsic) and tissue factor (extrinsic) pathway which together 
unite to activate thrombin and form the fibrin plug (Figure 1) [12, 13]. Many of 
the anticoagulant medications focus on altering the steps herein, and the inher-
ited coagulopathic disorders also feature abnormalities at various steps in the 
pathway [13, 14]. BSMs also interact here, as the so-called active agents contain 
thrombin and fibrinogen components, whereas passive agents rely on an already 
intact cascade [5].
Figure 1. 
Overview of coagulation cascade. Diagram of the multistep intrinsic (left, blue) and extrinsic pathway 
(right, green). Whether initiated by surface contact or tissue damage, both pathways combine into the common 
pathway leading to activation of factor X and then subsequent thrombin-fibrin activation and finally 
formation of the fibrin clot. Legend demonstrates where hemostatic agents, mechanical, and adhesive hemostats 
exert their roles in the coagulation cascade.
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4. Adhesive hemostats
Adhesive agents, whether liquid or fibrin patch, contain thrombin and fibrin 
thereby facilitating the final steps of the coagulation cascade [5, 11]. These added 
factors may help facilitate hemostasis in patients with various functional impair-
ments within the coagulation cascade [15, 16]. Alterations within the coagulation 
mechanism that lead to the so-called “non-surgical bleeding” may be due to 
coagulopathy of massive traumatic hemorrhage, large intraoperative blood losses, 
or sepsis secondary to gastrointestinal perforation [8, 17–20]. Within the broader 
context of surgical “damage control” emerges perhaps the most compelling use 
case for BSMs [21, 22].
Historically, adhesive preparations contained additional antifibrinolytic 
components such as tranexamic acid (TXA) and aprotinin, which are no longer 
utilized due to reported side effects in cardiac surgery, including anaphylaxis, 
renal failure, increased mortality (aprotinin), and neurotoxicity (tranexamic acid) 
[23–25]. There are several liquid formulations of adhesive hemostats and “patch” 
alternatives available today (Table 1) [5]. Liquid adhesives are easily applied to 
delicate tissue, while fibrin patch alternatives can be more bluntly applied to brisk 
hemorrhage thereby providing improved hemostasis for various tissue types [5]. 
Adhesive
Name Manufacturer Mechanism Form Comment
Beriplast CSL Behring LLC 
King of Prussia, PA, 
USA
Thrombin/fibrin Liquid Hemostasis on 
native and PTFE 
surfaces
Evicel Omrix LTD Ness 
Ziona, IL, USA
Thrombin/fibrin Liquid Hemostasis on 
native and PTFE 
anastomosis, help 
with dural suture 
lines
Floseal Baxter Inc. Deerfeild, 
IL, USA
Thrombin/
fibrin+porcine gelatine
Liquid
Qubeil Omrix LTD Ness 
Ziona, IL, USA
Thrombin/fibrin Liquid
Surgiflo J & J Healthcare 
Hacketstown, NJ, 
USA
Thrombin/
fibrin+porcine gelatin
Liquid
Tisseal Baxter Inc. Deerfeild, 
IL, USA
Thrombin/fibrin Liquid Hemostasis on 
native and PTFE 
surfaces
Evarrest Omrix LTD Ness 
Ziona, IL USA
Thrombin/fibrin Patch Patch provides 
added compression
Tachosil Baxter Inc. Deerfeild, 
IL USA
Thrombìn/
fibrin+equine collagen 
patch
Patch Patch provides 
added compression, 
hemostasis on 
portal and hepatic 
artery anastomosis
Use when coagulation cascade impaired. Do not use in the setting of allergy to blood products. 
Thromboembolic risk with intravascular administration
Overview of adhesive hemostats name, manufacturer, mechanism, and form.
Table 1. 
Adhesive hemostats.
Biosurgicals - The Next Frontier in Operative Approaches
4
Among available products, different brands have their own unique fibrinogen/
thrombin ratio affecting clot strength and drying time [5, 9, 26]. In general, 
higher thrombin concentrations correlate with the rate of clot formation whereas 
increased fibrinogen levels are associated with overall clot strength, which is not 
surprising as thrombin functions more proximally to fibrinogen, acting as a limit-
ing reagent in the coagulation cascade, whereas fibrinogen more directly affects 
fibrin levels within the fibrin plug (Figure 1) [27–33].
Clinical trials focused on controlling intrabdominal and retroperitoneal hem-
orrhage have demonstrated that adhesive hemostats containing fibrin/thrombin 
coagulation factors tend to be superior to hemostats lacking these components [5]. 
A number of vascular surgery studies have shown significant improvement in the 
rate of hemostasis on native and polytetrafluoroethylene (PTFE) arterial anasto-
mosis with several such agents (Table 1) [25, 34, 35]. In neurosurgical applications, 
another thrombin/fibrin adhesive was shown effective in helping to seal dural 
suture line leaks [36, 37]. For abdominal applications, one type of a hemostatic hon-
eycomb patch matrix with added fibrin and thrombin factors was shown to reduce 
anastomotic bleeding following portal vein repair and hepatic artery reconstruction 
(Table 1) [5, 38]. However, there are conflicting data on whether these hemostatic 
agents can reduce the incidence of “structural” (versus “hemostatic”) events, such 
as postoperative pancreatic fistula following distal pancreatectomy, bile leakage 
status post hepatectomy, and persistent air leak after thoracic surgery [5].
5. Mechanical hemostats
Mechanical hemostats typically consist of cellulose, collagen, gelatin, and other 
plant-based materials [39–41]. The composition of these BSMs differs from the 
adhesive hemostats, as they lack coagulation factors and therefore require a func-
tioning coagulation cascade to exert their effects [5]. Their mechanism of action 
relies on the absorbent capacity of the material, thereby exerting mass effect on 
the adjacent tissue and subsequent activation of the extrinsic coagulation pathway 
(Figure 1) [9, 42, 43].
6. Cellulose
Oxidized cellulose based hemostats are classified according to the way they 
are processed (regenerated versus non-regenerated) [5]. In short, the regenerated 
products have a more organized structure and conform better to their surround-
ings in comparison to the latter. Despite this, multiple studies have demonstrated 
greater hemostatic capacity for the non-regenerated products [44–46]. There are 
numerous products based on oxidized regenerated cellulose as the primary BSM, 
with relatively fewer non-regenerated products (Table 2) [5, 46]. In compari-
son to the adhesive hemostats, mechanical products are generally easier to use, 
relatively less expensive, and also exhibit bacteriostatic properties due to their low 
pH [20, 47–49]. Even though cellulose degrades within approximately 5 weeks, 
one limitation to its use includes the increased formation of granulation tissue 
months afterwards, which may produce a mass effect on vessels with subsequent 
stenosis or paralysis if adjacent nerves are compressed [50–54]. Moreover, the 
postoperative course for cancer patients may become significantly more compli-
cated if granulation tissue results in a pseudotumor following the resection of the 
recurrent mass [50–55].
5Operative Hemostasis in Trauma and Acute Care Surgery: The Role of Biosurgical Agents
DOI: http://dx.doi.org/10.5772/intechopen.94100
7. Collagen-based biosurgicals
Collagen is a key component of extracellular membranes and, as such, a great 
deal of effort has been placed into bioengineering collagen-based biosurgicals 
(CBBs) [56]. Additionally it is thought that such hemostats would also facilitate 
wound healing and potentially assist in neovascularization [56]. One CBB is 
known to improve perioperative hemostasis during craniotomy, and similar 
collagen based materials were shown to improve hemostasis during gynecologi-
cal procedures (Table 2) [57, 58]. A recently bioengineered product containing 
cellulose, chitosan, and oxidized bacterial cellulose was shown to be both bacteri-
cidal and hemostatic in an animal model of liver injury, comparing favorably to a 
commonly used alternative [59].
8. Gelatin-based mechanical hemostats
Gelatin based mechanical hemostats which are either bovine- or porcine-based, 
have a neutral pH permitting combination with thrombin adhesives [60]. Therefore 
their hemostatic function extends into two domains, including both “absorptive-
mediated” activation of the extrinsic pathway in addition to facilitating the final 
steps of the thrombin-fibrin cascade [5, 61]. In terms of biodegradation, gelatin 
sponge, granule, and powder dissolves within approximately 6 weeks of placement 
Mechanical
Name Manufacturer Mechanism Form Comment
Surgicel Ethicon 
Somerville, NJ, 
USA
Oxidized 
celluose
Sheet
Surgicel Fibrillar Ethicon 
Somerville, NJ, 
USA
Oxidized 
celluose
Sheet
Surgicel Nu-kit J & J Healthcare 
Hacketstown, NJ, 
USA
Oxidized 
celluose
Sheet
Traumastem Bloster Veverská 
Bitẏŝka, Czech 
Republic
Oxidized 
celluose
Sheet
Avitene Bard Warwick, 
RI, USA
Collagen Sheet/sponge/
powder
Hemostasis 
during 
crainiotomy
Gelfoarm Pfizer NY, NY, 
USA
porcine gelatin Sponge
Arista Bard Warwick, 
RI, USA
polysaccharide 
spheres
Powder Improved 
hemostatis in 
cardiothoracic 
surgery
Need normal coagulation cascade. Low pH with bacteriacidal properties. Thromboembolic risk with 
intravascular infection.
Overview of mechanical hemostats name, manufacturer, mechanism, and form.
Table 2. 
Mechanical hemostats.
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[5]. Both gelatin- and collagen-based hemostats are effective in reducing periopera-
tive blood loss. Additionally, neurosurgical models suggest that collagen-based 
products may be superior in controlling hemorrhage in spinal fusion procedures 
[62]. Although collagen- and gelatin-based products may be less expensive than 
fibrin products, one negative aspect is that when actively using blood saving tech-
niques (e.g., cell-saver device), these products may pass through 20 micron filters 
leading to an inflammatory renal response [63].
Another mechanical hemostat category is derived from plant starch and is 
known as a microporous polysaccharide hemosphere (MPH) (Table 2) [64]. 
This highly absorbent product works similar to collagen and gelatin formulations 
through activation of the extrinsic clotting cascade. However, in comparison 
to collagen and gelatin, sufficient evidence exists in cardiothoracic surgery to 
demonstrate improved hemorrhage control, reduced chest tube output and fewer 
perioperative blood product transfusions [5]. From orthopedic surgery perspective, 
MPH may be favored as it does not inhibit bone healing compared to bone wax or 
microfibrillar collagen [65]. Moreover, microporous hemospheres absorb blood 
rapidly and have less capacity to cause infection and granuloma than other biologic 
hemostats [5, 66].
9. Sealant hemostats
Sealant hemostats (SH) are a class of hemostatic polymers which form a matrix 
by crosslinking and interlocking protein-rich adjacent tissues. Interestingly, sealants 
neither require the presence of blood products nor an intact coagulation cascade 
to exert their effects [5]. Natural sealants are derived from proteins and polysac-
charides, while synthetic and semisynthetic products are composed of polyethylene 
glycol cyanoacrylate (PEG), polyurethane, dendrimer, and glutaraldehyde albumin 
biomaterials [67, 68]. Composite sealants contain both natural and synthetic com-
ponents. All have been exploited for hemostasis, wound healing, fistula repair and 
implant fixation in fields such as cardiothoracic, biliary, urologic, plastic, neuro, 
and endoscopic surgery [68].
Natural fibrin based sealants are a mixture of fibrinogen and thrombin and 
come in either dry or foam preparations. They are mainly used to decrease suture 
and staple line seepage [56, 68]. Other proteins utilized in sealant applications 
include collagen, keratin, albumin, as well as muscle-derived products [68]. 
Polysaccharide compounds include chitosan, alginates, and chondroitin sulfates 
[69, 70]. A recent phase III clinical trial revealed that a fibrin-based sealant can pro-
vide excellent hemostasis, potentially superior to manual compression in patients 
undergoing open arterial surgery [71]. Interestingly, some of the well-known fibrin-
based hemostats which leverage the coagulation cascade as the primary mechanism 
of action also exhibit a sealant function via covalent interactions with the surround-
ing tissues [56]. Even though fibrin sealants may be less effective in blood-saturated 
tissues, the potential benefit of an added “sealant feature” provided insight into 
research on new hemostatic sealants characterized by increased overall strength, 
elasticity, and stronger covalent interactions with surrounding tissues [72]. Other 
limitations of fibrin sealants include increased price compared to synthetic prod-
ucts, as well as high reliance on human plasma products for manufacturing pur-
poses thereby increasing the risk, albeit very low, of transmissible disease [56].
PEG based products can be prepared in both patch and liquid formats to func-
tion as both hemostatic sealants and fluid barriers (Table 3) [5, 56]. There are patch 
products infused with collagen or cellulose, with superior hemostatic properties 
(Table 3) [5, 73]. Studies show less bleeding around anastomotic suture lines in 
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nephrectomy and coronary artery bypass procedures with the use of bovine colla-
gen and pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate patch 
[44, 46]. Similarly, a combined PEG and oxidized cellulose product significantly 
reduced oozing in hepatectomy procedures [74]. Another related product is effec-
tive as a fluid barrier and significantly improves closure of the dura during spinal 
surgery [75–77]. Finally, PEG-albumin sealants appear to be able to similarly reduce 
air leaks following pulmonary lobectomy procedures [44, 78, 79].
Polyurethane sealants have great potential and promise due to their highly 
elastic properties. Of importance, in an animal abdominoplasty model, this type 
of sealant was found to reduce seroma formation [56]. However there are safety 
concerns due to the potential thrombotic risk associated with similar products [56].
It is important to note that hemostatic sealants are not without risks, and their 
limitations include some concerns regarding the strength of the deployed material 
as well as some degree of interference with wound healing [68]. Although synthetic 
sealants have increased elasticity compared to natural counterparts, their limita-
tions include longer curing time, the potential for chronic inflammation and the 
risk of cytotoxicity [56]. Moreover, PEG-based sealants should not be used in renal 
insufficiency as they are dependent on renal clearance following their breakdown 
and absorption [5]. Of note, PEG-sealants also tend to swell prior to degrading, 
which does provide tamponade assisting in hemostasis, but may be detrimental if 
applied within closed spaces that contain neurovascular structures or ureters [56]. 
Cyanoacrylates similar to those used in skin closure for improved cosmetic out-
come, when used in large quantities, can produce significant amounts of heat and 
potentially lead to tissue damage [5]. Additionally, these products cannot be used 
intravascularly, or directly on vascular anastomoses, due to risk of embolization (in 
Sealants
Name Manufacturer Mechanism Form Other
Hemopatch Baxter Deerfeild, 
IL, USA
PEG/collagen Patch Data to support use 
in nephrectomles and 
CABG
Duraseal Integra Palinsboro 
township, NJ, uSa
PEG Liquid Improves dural closure
Veriset Covidien 
Walpole, MA, 
USA
PEG/cellulose Patch Decreased bleeding 
after hepatectomy
FocalSeal Focal Inc. 
Lexington, ma, 
USA
Eosin primer/PEG Liquid Decreased air leak after 
lobectomy
TissuGlu Cohera Medical 
Oplotnica, 
Solvania
Polyurethane Liquid
Dermabond Ethicon 
Somerville, NJ, 
USA
Cryanoacylate Liquid Exothermic reaction
Bioglue CryoLife 
Kennesaw, GA, 
USA
glutaraldehyde-
bovine albumin
Liquid Safe for vascular 
anastomosis
Do not use with renal disease patient’s
Overview of hemostatic sealants name, manufacturer, mechanism, and form.
Table 3. 
Hemostatic sealants.
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fact, the material can be utilized in therapeutic embolization and other hemostatic 
maneuvers) [80–82]. The glutaraldehyde-bovine albumin, on the other hand, is safe 
and effective to directly apply on vascular and cardiac anastomotic suture sites [5]. 
Moreover, the use of this type of substance was shown to reduce blood transfusion 
requirements postoperatively, appears to be safe on adjacent nerves, and carries 
only a limited risk of vascular anastomotic stenosis secondary to an inflammatory 
response if the product is applied circumferentially [5].
10. Hemostatic dressings
Mineral-based and polysaccharide containing hemostatic dressings are of great 
value for pre-hospital exsanguinating patients, especially when protective measures 
such as tourniquet placement are not feasible due to the anatomical location of the 
wound [83, 84]. Such dressings are classified based on their mechanism of action, 
and include factor concentrators, muco-adhesives, or procoagulants [5]. Factor con-
centrators composed of volcanic or clay minerals such as zeolite and smectite act by 
concentrating protein components of blood thereby facilitating clot formation. The 
most commonly used factor concentrator is composed of zeolite beads which can 
be poured directly into a wound to expedite hemostasis (Table 4). One downside 
of this product is that it releases significant amounts of heat in a highly exothermic 
reaction. Consequently, care must be taken to use this preparation externally only, 
with applications limited to quantities “as little as necessary” to stop external bleed-
ing [5]. Muco-adhesive products consist of the polymer chitosan, a chitin based 
product, which is derived from crustacean exoskeleton material [85]. Interestingly, 
chitosan has no intrinsic hemostatic ability, but its chemical charge is opposite to 
erythrocytes, thus promoting hemostasis [86, 87].
Procoagulant hemostats work by actively facilitating the coagulation cascade. 
One product, known as “combat gauze,” consists of surgical dressing coated with 
the mineral kaolin (Table 4) [88]. Kaolin is a nonreactive mineral that activates 
the intrinsic, contact-mediated clotting pathway when it comes in direct contact 
with damaged tissue [5]. The product is non-absorbable and must be removed after 
hemostasis is achieved, but does not create the exothermic reaction observed in 
factor concentrators. Baker and colleagues demonstrated that a novel fibrin-based 
sealant was equally effective when compared to “combat gauze” in a porcine model 
of both hepatic and femoral artery injury [89]. Similarly, this novel fibrin sealant 
was also shown to be superior other formulations in a similar swine model of splenic 
Hemostatic
Name Manufacturer Mechanism Form Other
Quick clot Z-Medica LLC 
Wallingford, CT, USA
Zeolite 
beads
Guaze Exothermic reaction. Needs 
to be removed from wound.
HemCon Tricol Biomedical 
Portland, OR, USA
Chitin Gauze Exothermic reaction. Needs 
to be removed from wound.
Quick clot 
Combat Guaze
Z-Medica LLC 
Wallingford, CT, USA
Kaolin Gauze Exothermic reaction. Needs 
to be removed from wound.
Use externally for significant bleeding
Overview of hemostatic agents separated by name, manufacturer, mechanism, and formulation.
Table 4. 
Hemostatic agents.
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laceration [90]. Further studies are ongoing in this important and rapidly develop-
ing area of clinical investigation.
11. Future directions and conclusion
The ideal surgical hemostat should be biocompatible with its target tissues, safe, 
easy-to-use, and capable of providing rapid hemostasis. Importantly, BSMs should 
be able to operate under a broad range of conditions, possibly even when applied to 
actively bleeding or oozing surfaces, without being washed away or immediately los-
ing their potency. Additionally, the optimal hemostat should have sufficient strength 
to hold the tissues in place to accomplish tamponade and assist in further healing. 
In the field of trauma and acute care surgery BSMs should maintain high levels of 
effectiveness for at least several hours, only act on the intended target tissues, should 
preferably be biodegradable, and should not impair wound healing. Affordability 
and ease of application are also important considerations. Future product develop-
ment should also aim to incorporate, whenever possible, bactericidal properties. 
Moreover, novel materials may perform better if components like collagen are added 
to also assist in subsequent wound healing and maintenance of tissue integrity. 
Additionally, future research should aim to further understand the various tissue-
specific effects of surgical hemostats, as well as their molecular and cellular interac-
tions in order to individualize and optimize the resultant clinical outcomes.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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